Buscar
Mostrando ítems 1-10 de 231
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells
(MDPI AG, 2016)
Tumor angiogenesis is widely recognized as one of the hallmarks of cancer. Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and ...
Escaping antiangiogenic therapy: strategies employed by cancer cells.
(2016)
Tumor angiogenesis is widely recognized as one of the hallmarks of cancer. Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and ...
Escaping antiangiogenic therapy: strategies employed by cancer cells
(2016)
Tumor angiogenesis is widely recognized as one of the hallmarks of cancer. Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and ...
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells
(2016)
Tumor angiogenesis is widely recognized as one of the “hallmarks of cancer”. Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and ...
Experimental histopathological study on retinal and renal cellular response to intravitreous antiangiogenic drugs
(Ijo Press, 2014-06-18)
AIM: To evaluate histopathological retinal and renal response after one single dose of intravitreous injection of antiangiogenic drugs ranibizumab and bevacizumab in rats.METHODS: Experimental study in 60d of life adults ...
Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer
(2021)
: Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The late diagnosis is frequent due to the absence of specific symptomatology and the molecular complexity of the disease, which includes ...